Akeso Biopharma, Inc.

Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

Ad Pharmaceutical Co., Inc.

Taizhou Hanzhong Biopharmaceutics, Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Akeso Pharmaceuticals, Inc.

Zeda Biopharmaceuticals, Inc.

Cttq-akeso (shanghai) Biomed. Tech. Co., Ltd.

Cttq-akeso Biomed. Tech. Co., Ltd.

Baiyong Li

Yu Xia

Zhongmin Maxwell Wang

Peng Zhang

Xinghua Pang

Jingyi Wang

Lichun Wang

Ying Huang

Tongtong Xue

Liang Xiao

Yuanyuan Xu

Faming Zhang

Gan Xi

Dongsheng Dai

Jinan Jiao

Wuxian Ren

Xiquan Zhang

Xin Tian

Rong Li

Xiangjian Wang

Zheng Liu

Hua Zhong

Baohui Han

Tianqing Chu

Peng Lyu

Xiaoping Jin

Chen Shen

The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.

Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses

The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.

Therapeutic combination of quinoline derivative and antibody

The present invention belongs to the field of immunology, and relates to an anti-IL-1β antibody and pharmaceutical composition thereof and use of the same. Specifically, the present invention relates to an anti-IL-1β antibody or an antigen-binding fragment thereof, wherein a heavy chain variable region of the antibody comprises HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NO: 17-SEQ ID NO: 19, respectively; and a light chain variable region of the antibody comprises LCDR1-LCDR3 set forth in SEQ ID NO: 20-SEQ ID NO: 22, respectively. The antibody disclosed herein can effectively bind to human IL-1B, block the binding of IL-1B to a receptor IL-1R1 thereof, and inhibit the activation of downstream signaling pathways of IL-1B; having the potential of being used for preparing a medicament for preventing and treating autoimmune diseases, cryopyrin-associated periodic syndromes in children and adults, systemic juvenile idiopathic arthritis, gouty arthritis, cardiovascular diseases or tumors.

Anti-IL-1β antibody and pharmaceutical composition thereof and use of same

The present application relates to the fields of tumor treatment and molecular immunology, and specifically, to an anti-VEGFA/PD-1 bifunctional antibody, a pharmaceutical composition thereof and use thereof. Specifically, the anti-VEGFA/PD-1 bifunctional antibody comprises an antibody or antigen binding fragment thereof targeting VEGFA and an antibody or antigen binding fragment thereof targeting PD-1. The bifunctional antibody can specifically bind to VEGFA and PD-1, specifically relieve immunosuppression of VEGFA and PD-1 in an organism, and inhibit tumor-induced angiogenesis.

Anti-PD-1/VEGFA bifunctional antibody, pharmaceutical composition thereof

An anti-PDl (programmed cell death 1) monoclonal antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof and use thereof. The heavy chain variable region of the monoclonal antibody comprises CDRs (complementary determining region) of amino acid sequences as shown in SEQ ID NO:9-11; and/or the light chain variable region of the monoclonal antibody comprises CDRs of amino acid sequences as shown in SEQ ID NO: 12-14. The monoclonal antibody can bind to PDl specifically, relieve immunosuppression of PDl on an organism specifically and activate T lymphocytes.

Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Provided are antibodies or antigen binding fragments thereof, which can bind to human IL-1β, block the binding of IL-1β to receptors thereof and thereby down regulate the activity of IL-1β, and can be used to prepare drugs for the treatment of immune diseases mediated by IL-1β overexpression such as arthritis, osteoporosis, and tumor necrosis factor receptor-associated periodic syndrome.

Antibody binding to human IL-1β, preparation method therefor and use thereof

The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody against nerve growth factor of the present invention comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody against nerve growth factor of the present invention can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and to prepare a drug for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

Monoclonal antibody against nerve growth factor, and encoding gene and use thereof

An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.

Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof

The present invention belongs to the fields of tumor therapy and molecular immunology. The present invention relates to an anti-CTLA4 antibody, pharmaceutical composition and use thereof. The anti-CTLA4 antibody of the present invention can specifically bind CTLA4, and can very effectively block the binding of CLTA4 to B7.

Anti-CTLA4 antibodies

The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.

Nucleic acid encoding PCSK9 antibody

The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.

PDL-1 antibody, pharmaceutical composition thereof, and uses thereof

Proposed is an anti-PD-1 monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region having at least one of the amino acid sequences listed below: (1) the amino acid sequence shown in SEQ ID NO: 1; (2) the amino acid sequence shown in SEQ ID NO: 3; (3) the amino acid sequence shown in SEQ ID NO: 5; and (4) an amino acid sequence having more than one conservative amino acid mutation compared with (1)-(3).

Anti-PD-1 monoclonal antibody

Provided is a monoclonal antibody against programmed death-1 (PD-1) or applications thereof, where the monoclonal antibody against PD-1 comprises a neonatal Fc Receptor (FcRn)-binding site having an amino acid sequence of SEQ ID NO: 5.

Growing community of inventors

Guangdong, China

Baiyong Li